GlassScriptPhysician profile
Katina B Miles
NPI 1053460568
$9,838.89
in general payments reported to CMS, 2019-2025
35 companies · $2,527 in 2025
The $2,527 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $472 · 2021: $1,039 · 2022: $995 · 2023: $1,509 · 2024: $1,778 · 2025: $2,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,610 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,610.32 |
| Education | $203.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,132.07 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,028.33 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Dermavant Sciences, INC. | $1,003.38 | 2022-2024 | Vtama |
| Abbvie INC. | $948.56 | 2019-2025 | |
| Incyte Corporation | $801.63 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $623.08 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $460.68 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $452.94 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $407.49 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Merz North America, INC. | $336.39 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $324.59 | 2019-2025 | Winlevi, Absorica Ld |
| Organon LLC | $322.06 | 2025 | Vtama |
| Leo Pharma INC. | $278.62 | 2019-2025 | Anzupgo |
| Arcutis Biotherapeutics, INC. | $243.93 | 2023-2025 | Zoryve |
| Botanix Sb INC | $163.63 | 2025 | Sofdra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $157.17 | 2019-2021 | |
| Celgene Corporation | $130.16 | 2019 | |
| Ucb, INC. | $122.25 | 2023-2024 | Bimzelx, Cimzia |
| Almirall LLC | $109.77 | 2019-2022 | |
| Genzyme Corporation | $90.20 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $81.92 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $77.24 | 2019-2022 | |
| Journey Medical Corporation | $74.00 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $66.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.95 | 2019-2025 | |
| Lumenis, INC | $59.23 | 2021 | |
| Amgen INC. | $56.57 | 2020-2024 | Otezla |
| Vyne Pharmaceuticals INC. | $38.84 | 2020-2021 | |
| Encore Dermatology INC. | $36.24 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $35.81 | 2019-2021 | |
| Organogenesis INC. | $32.86 | 2025 | Apligraf |
| Epi Health, LLC | $32.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.16 | 2023 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $19.08 | 2020 | |
| Glenmark Therapeutics INC. | $6.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katina Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.